KYNB
Kyntra BioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings company update preserved the main upside hooks: FG-3246 enrollment is continuing toward a 4Q 2026 interim readout, roxadustat moved to protocol finalization after FDA feedback, and cash, cash equivalents, investments, and accounts receivable were reported at $100.3 million, reducing immediate financing pressure.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical execution remains binary, with FG-3246 enrollment and eventual interim efficacy/safety data still the primary value driver.
Momentum
95
Value
58
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $10.50 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $43.00
Why
Momentum95 · Δ7d -
Value58 · Δ7d +0.2
Sentiment47 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.3
Sentiment
47
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 94.6 / Value 57.9 / Sentiment 47.5
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$27.93M
Beta
0.84
Shares Out
4.05M
P/E (TTM)
0.2
P/S (TTM)
4.35
P/FCF (TTM) · Derived
-1.63
Rev YoY
+774.8%
EPS YoY
+72.9%
Gross Margin
+345.7%
Op Margin
-1574.1%
Net Debt
$39.73M
Current Ratio
3.71
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology